We are pleased to announce the Slate of Nominees standing for election to the next Board of Directors including the following positions: Vice President (2022-2023), Secretary (2022-2024), Treasurer (2022-2024), ESDE Director (2022-2024) and four Director positions (2022-2024). We would like to thank all candidates willing to stand for election.
The online election period is June 13-30, 2022. On June 13 all ISDE members will receive an email containing a unique election ID link. Electors will simply click on the link to cast their anonymous votes.
2022 Board of Directors Candidates
VICE President (2022-2023)
It is an honour to humbly submit my candidacy for the position of vice president of the ISDE, a society I have faithfully served since attending my first meeting in Adelaide over 15 years ago. I am an esophageal surgeon at McGill University in Montreal Canada and director of the division of Thoracic and Upper Gastrointestinal Surgery at this institution.
In addition to being an active clinician directing the multidisciplinary McGill University Program in Upper Gastrointestinal Cancers, I am a tenured professor and scientist in the Departments of Surgery and Oncology. Through these roles, I have spearheaded numerous initiatives designed to improve outcomes in esophageal surgery and upper GI cancer through carefully coordinated basic, translational, and clinical scientific research.
Over the past 20 years I have been fortunate to have benefited from numerous peer review grants from funding agencies in North America and Europe for my work into the inflammatory basis of cancer progression and metastasis. In 2019, I was a part of an international team of scientists who received a Cancer Research UK Grand Challenge to investigate the stromal drivers underpinning Barrett’s adenocarcinoma progression.
My roles in ISDE include being the program co-chair of the 2020-2021 ISDE World Congress and serving as associate editor of the Disease of the Esophagus journal since 2015. I look forward to hopefully continuing my service to the ISDE as Vice President.
Baylor University Medical Center
Dallas, TX (USA)
Vani J.A. Konda, MD is a gastroenterologist with clinical expertise in esophageal diseases including Barrett's esophagus, early esophageal cancer, achalasia, swallowing disorders, eosinophilic esophagitis, reflux, and complex esophageal strictures. She completed her residency and fellowship training and remained on faculty at University of Chicago in Chicago, Illinois. Since 2017, she has served as the Medical Director at the Baylor Scott and White Center for Esophageal Diseases at Baylor University Medical Center in Dallas, Texas. Collaborating with other gastroenterologists, surgeons, and otolaryngologists, she has developed a clinical multidisciplinary program for complex benign and malignant disorders of the esophagus. She actively participates in a unique multidisciplinary, translational research program at the Baylor Scott and White Center for Esophageal Research. Her research interests have focused primarily on premalignant lesions of the gastrointestinal tract, in particular Barrett’s esophagus and advanced endoscopic imaging. She has authored over 100 articles, book chapters, and videos. She has been active in the International Society of Diseases of the Esophagus (ISDE) on the Board of Directors and as Communications Committee Co-chair and in the three major national societies, American Society of Gastrointestinal Endoscopy (ASGE), American Gastroenterological Association (AGA), and the American College of Gastroenterology (ACG).
Toho University Graduate School of Medicine
I am professor of the Department of Surgery and Clinical Oncology, of Toho University, Tokyo, Japan. My main clinical work is dedicated to esophageal and gastric cancer surgery. I'm in charge of the guidelines for the treatment of esophageal cancer and gastric cancer. My main research & scientific interests are immunotherapy and biomarkers to improve overall prognosis of cancer patients. I am scheduled to be a president of the Annual congress of Japanese Esophageal Society in September, 2022. I have been a board member and program committee of ISDE. I am very pleased and honored to be given the opportunity to take charge of financial operations as a Treasurer at the ISDE Board. I also want to take full advantage of the opportunities to work to develop international cooperation for the benefit of ISDE and its members.
ESDE DIRECTOR (2022-2024)
Richard Van Hillegersberg
Richard van Hillegersberg attended medical school in Rotterdam, the Netherlands. In 1993 he received his PhD with honor at the Department of Surgery, Erasmus MC in Rotterdam. From 1994-2000, he was trained in General Surgery in Rotterdam. From 2001-2002 he was fellow of Surgical Oncology in the Academic Medical Center and Antoni van Leeuwenhoek Netherlands Cancer Center Amsterdam. Since 2003 he is appointed as staff surgeon at the University Medical Center Utrecht. From 2009 he is a full professor of gastrointestinal oncology. Research is focused on Upper GI minimally invasive and robotic surgery, surgical imaging and genetic profiling. He has authored over 15 chapters in textbooks concerning robotic forgut surgery and over 500 articles in international peer-reviewed journals. From 2018 he is chairman of the Educational committee of the European Society for Diseases for the Esophagus (ESDE) and member of the education committee of ISDE, he is associate editor of Diseases of the Esophagus and Digestive Surgery, founder and chairman of the Upper GI International Robotic Association (UGIRA).
It is a great honor for me to be nominated as Director of the ISDE Board. I am currently a consultant upper-GI surgeon and principal investigator at the Amsterdam UMC, University of Amsterdam in Amsterdam, The Netherlands. I have been proctoring minimally invasive esophagectomies and gastrectomies at different centers in the Netherlands and abroad. My main research topics are lymph node metastases and extent of lymphadenectomy in esophageal and gastric cancer (e.g. the international TIGER-study), minimally invasive upper GI surgery and postoperative outcome, quality of life following upper GI surgery and surgical techniques (e.g. RCT omentectomy vs omentum preservation in gastrectomy – OMEGA-trial, transhiatal versus transthoracic esophagectomy – national IVORY-study).
Currently, I serve as board member of the Dutch Society for Gastro-Intestinal Surgery (NVGIC) and of the European Society for Diseases of the Esophagus (ESDE). Also, I am a member of the scientific committee of the ESDE/IGCA-joint 2021 congress, the ISDE 2022 world congress, and in the organization of the future ESDE and 2025 IGCC congresses, which will be organized in Amsterdam. Furthermore, I contribute to several other (guideline) committees.
The ISDE is a very important society to me, bringing together disciplines involved in treatment of esophageal diseases from all over the world. This multidisciplinary approach is of great significance. I am an active member since 2013, and have attended all congresses since 2014. I have served on several ISDE committees previously and currently such as the Research & Database Committee; Esodata Membership Bylaws and Budget Subcommittee, the Membership Committee (chair) and the Guidelines Committee.
I would be honored if I would be given the opportunity to serve as a director in the ISDE board and would make great effort to further develop multidisciplinary and international collaboration in the interests of the international society for diseases of the esophagus.
Wayne L. Hofstetter, M.D., is currently Professor and Deputy Chair in the Department of Thoracic and Cardiovascular Surgery and serves as Director of the Esophageal Surgery Program. A graduate of the University of Southern California Medical School, Dr. Hofstetter focused on thoracic surgical disease, completing fellowships in esophageal and foregut surgeries at the University of Southern California, and then thoracic oncology at M. D. Anderson Cancer Center. Broadly trained as a cardiothoracic surgeon and thoracic oncologist at the Texas Heart Institute, he now devotes a great deal of his work to esophageal cancer and lung cancer. At M. D. Anderson, he formed a strong network of clinicians with specific interests in esophageal diseases. A multidisciplinary group emerged under his able leadership, and together, physicians from other specialties like Gastrointestinal Medical Oncology, Radiation Oncology, and Gastroenterology collaborate closely to treat esophageal cancer patients.
I am a medical oncologist and chief of Department of Head and Neck, and Esophageal Medical Oncology, and Gastrointestinal Medical Oncology, National Cancer Center Hospital, 2020-2022, and chief, Biobank Translational Research Support Section, Clinical Research Coordinating Section, Clinical Research Support Office, National Cancer Center Hospital. My primary interest is chemotherapy and chemoradiotherapy for oesophageal, esophagogastric, and gastric cancer. I am a group coordinator of the Japan Esophageal Oncology Group of JCOG, the most significant clinical trial group for cancer in Japan.
Our group has conducted clinical trials to develop new chemotherapy for metastatic disease and early oesophageal cancer in multimodality therapy. As a study coordinator, I conducted the randomized phase III trial, which compared the surgery and chemoradiotherapy for clinical stage I oesophageal squamous carcinoma, named JCOG0502, which reported the non-inferiority of chemoradiotherapy to surgery. The randomized phase III trial of neoadjuvant therapy for resectable oesophageal squamous cell carcinoma, named JCOG1109, showed superior survival of triplet-chemotherapy over doublet-chemotherapy. This trial gave a new aspect to neoadjuvant therapy for esophageal cancer.
To develop new drugs, such as immune-checkpoint inhibitors, I committed to the international phase III trial of oesophageal cancer as a steering committee member, for example, ATTRACTION-3 KEYNOTE-590, CheckMate-649, RATIONALE-306, and others.
I am a director of the Japan Esophageal Society (JES) and am committed to international conferences in Asia and the public relations activity of JES. I am honored to be considered for this position, and if selected, I will work hard to promote the ISDE in national and international venues.
Dr. Vaezi is currently a Professor of Medicine and Otolaryngology at the Vanderbilt University Medical Center in the Division of Gastroenterology, Hepatology and Nutrition. He is the Associate Chief and Clinical Director of the Division and Director of Center for Swallowing and Esophageal Disorders and Director of Clinical Research. He is immediate past Chair of the EGD Section of the AGA and is currently Associate Editor for Gastroenterology and member of the AGA research Council.
Dr. Vaezi received a B.S. degree in Chemistry at Birmingham-Southern College in Birmingham, Alabama. He then went to the University of Alabama at Birmingham and received his Ph.D. in Bio-Organic Chemistry. From there, Dr. Vaezi went to the University of Alabama School of Medicine were he received his MD degree in 1992. He completed a four-year academic residency in internal medicine in program focused on clinical research at the University of Alabama Hospitals in Birmingham Alabama. Subsequently, he completed his fellowship in Gastroenterology at the Cleveland Clinic Foundation where he was elected as the Chief Fellow. He also received a Master’s in Epidemiology and Clinical Research from Case Western Reserve University.
Dr. Vaezi is an associate member of the American Gastroenterological Association, and a Fellow member of the American College of Gastroenterology.
ISDE News Corner